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Abstract
Background: The majority of children with eczema in the UK are looked after in primary care yet
we know little about their care in this setting.
Aim: To compare the diagnosis, assessment, and treatment of eczema in primary care with
published diagnostic criteria and management guidelines.
Design & setting: Cross-sectional study using data from a randomised controlled feasibility study.
General practices, UK.
Method: Baseline data from children aged 1 month to 5 years recruited ‘in-consultation’ for the
Choice of Moisturiser in Eczema Treatment (COMET) feasibility study was used. These included
clinician diagnosis and global severity assessment; the parent-completed Patient Orientated
Eczema Measure (POEM); a questionnaire about eczema treatments, including use of topical
corticosteroid (TCS); and, the Eczema Area Severity Index (EASI) carried out by trained researchers.
Descriptive analyses were undertaken to compare diagnoses with UK diagnostic criteria, severity
assessments, and treatment with the National Institute for Health and Care Excellent (NICE)
guidance.
Results: Data were available for 90 participants. Only 46% of participants labelled as having
eczema met the UK diagnostic criteria. Agreement between the global severity assessment by a
healthcare practitioner with the EASI and POEM measures of eczema severity were 44% and 48%
respectively. Emollients and TCSs were underused with 44% of participants not using any emollient
and 46% using one or more TCSs. The ‘match’ between eczema severity and TCSs potency was
poor.
Conclusion: Discrepancies were found between the diagnosis, assessment, and treatment of
children with eczema in primary care, and UK diagnostic criteria and guidelines. Further
investigation to explore the reasons for this discordance, and whether it matters, is needed.
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How this fits in
Most children with eczema are diagnosed and managed in primary care but little is known about
their assessment or treatment. It was found that less than half of children diagnosed with eczema in
primary care met the UK atopic eczema diagnostic criteria. Agreement between clinician, parent,
and ‘objective’ assessments of severity was also limited. Reported non-use of an emollient was com-
mon and there was often a discordance between the topical corticosteroid (TCS) potency and
eczema severity.
Introduction
Eczema (also known as atopic eczema/dermatitis) is one of the most common childhood disorders
with high prevalence (0.2–24.6%) worldwide.1 The burden of the disease falls on pre-school aged
children although it persists in a significant proportion through to adulthood.2 It is characterised by
dry and itchy skin and can have a significant impact on the quality of life of the patient and their
family.3,4
In countries like the UK, the majority of children with eczema are managed exclusively by
GPs5, yet little is known about their diagnosis, assessment, or treatment in this setting. Emerson
et al6 found that of children with eczema in primary care, the majority (84%) had mild eczema, with
14% moderate, and 2% severe. However, this study is now dated (1998), and assessments were
based on a single dermatologist’s clinical opinion, and no patient-reported measures were
collected.
Treatment guidelines recommend the use of emollients as a leave-on treatment (250–500g
weekly) and as soap substitutes, with different types for different purposes.7 For eczema ’flares’,
NICE advocates the use of TCSs with a potency that matches eczema severity, such as mild TCSs for
mild eczema, or moderate TCSs for moderate eczema.7 Prescribing data in Scotland from 2000–
2001 indicated that emollients are underprescribed and TCSs are used too much and at an inappro-
priate potency.8
Using data from the COMET feasibility study,9 the authors sought to better understand how
eczema is currently diagnosed, assessed, and treated in primary care in the UK.
Method
The COMET study
Full details of the COMET study can be found in the protocol.9 The aim of the study was to deter-
mine the feasibility of recruiting young children with eczema and randomising them to one of four
commonly used leave-on emollients. To be eligible to take part, children had to be between
1 month and 5 years of age, have a clinical diagnosis of eczema, and not known to be sensitive or
allergic to any of the study emollients or their constituents.
Participants were recruited via 22 GP surgeries located in the West of England. All practices sent
letters to potentially eligible children asking them to contact the study team if they were interested
in taking part (the ‘self-referral’ pathway). The focus of this study is on participants who were
recruited by clinicians, GPs, practice nurses (PNs), or practice pharmacists (PPs) in the 16 practices
who recruited participants ‘in-consultation’.
Data collection
As part of the consultation in which patients were consented and randomised to the study, the
recruiting healthcare provider (HCP) made a global clinical assessment of eczema severity (clear,
mild, moderate, and severe) in accordance with NICE guidelines,7 (Box 1) and the parent or carer
was asked to complete POEM.10 A researcher subsequently collected data on the diagnosis as per
the UK atopic eczema diagnostic criteria (Supplementary Box 1)11 and eczema severity assessed
using EASI.12 Patient-reported eczema treatments, such as emollients, bath emollients, TCSs, topical
calcineurin inhibitors (TCI) were collected using parent or carer self-report.
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Data analysis
Analysis was done using Stata (version 13.1). POEM and EASI scores were calculated and categor-
ised as per published guidance.10,12 The Index of Multiple Deprivation score (IMD) was calculated
from the English IMD 2010 score (based on Lower Super Output Area) using the GeoConvert
web application from the UK Data Service Census Support.13 Fisher’s exact test was used to exam-
ine differences between assessments of eczema severity by individual and groups of HCPs. Percent-
age agreement between different assessments of eczema severity and TCSs potency were
calculated.
Box 1. Eczema severity assessment (taken from the NICE guideline CG57)7
Clear: normal skin, no evidence of active atopic eczema.
Mild: areas of dry skin, infrequent itching (with or without small areas of redness).
Moderate: areas of dry skin, frequent itching, redness (with or without excoriation and localised
skin thickening).
Severe: widespread areas of dry skin, incessant itching, redness (with or without excoriation,
extensive skin thickening, bleeding, oozing, cracking and alteration of pigmentation).
Number of children with 
GP/Nurse/Pharmacist clinical 
severity assessment
n = 90 (100%)
Number of children recruited by 
GP/Nurse/Pharmacist
n = 90 (100%)
Number of children attending 
baseline visit (data on 
baseline treatment and EASI 
score)
n = 79 (88.8%)
Number of children with baseline 
POEM score
n = 89 (98.9%)
Number of children with UK 
diagnostic criteria assessment 
n = 79 (88.8%) 
Figure 1. Participant flow.
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Results
Participant characteristics
Out of 197 participants, 90 were recruited ’in-consultation’ and were included in this analysis (Fig-
ure 1). The majority of patients recruited were of white-British ethnic origin (73%, Table 1). Other
participant characteristics are summarised in Table 1.
One parent or carer did not complete the POEM questionnaire, 10 participants did not attend
their baseline visit, and baseline data were not collected on one participant. Therefore, data for
POEM were available on 89 (99%); and UK diagnostic criteria and EASI on 79 (89%) of participants
(Figure 1). Thirty-two per cent (25/79) had an eczema diagnosis of over 12 months duration.
Eczema diagnosis and severity assessment
Forty-six per cent (36/79) of participants met the UK diagnostic criteria for atopic dermatitis. Clinical
assessments of eczema severity were done by 26 different HCPs (21 GPs, 4 PNs, and 1 PP). One GP
and one nurse each did 16 assessments (32/90 [36%] of total). Thirty-three per cent (26/80) of base-
line (when EASI was collected) assessments took place within 5 days and 80% (64/80) within 10 days
of referral (when the clinical and parent (POEM) outcome measures were collected).
HCPs assessed participants’ eczema as 4% clear, 61% mild, 31% moderate, and 3% severe
(Table 2). There was no evidence of a difference in severity scoring between the types of HCP (Fish-
er’s exact test P = 0.736, Supplementary Table 1) or individual assessors (Fisher’s exact test
P = 0.280).
There was variation in the categorisation of eczema severity between clinical, POEM, and EASI
(Table 2). Clinical and EASI assessments categorised 61% of participants as having ‘mild’ eczema,
whereas according to the parent-reported measure POEM, more participants had ‘moderate’ (56%)
eczema. Agreement between clinical assessment and EASI was 44% (35/79, Supplementary Table
2); and clinical assessment and POEM was 48% (43/89, Supplementary Table 3).
Treatment: emollients and topical corticosteroids
Forty-four per cent (35/79) of said they were not using any emollient, while 41% (32/79) of the partic-
ipants were only using one. Sixteen different brands were named (Supplementary Table 4). The
majority (44/79, 56%) of participants were not using a bath emollient.
Forty-six per cent (36/79) of participants reported using one or more TCSs. Four reported using
two different types of TCSs, and two of these were using two of mild potency. One participant was
using three different types TCSs (two mild, and one potent). TCSs potency were as follows: 41% (32/
79) mild, 4% (3/79) moderate, and 5% (4/79) potent TCSs. Nine different types of TCSs were used
by respondersparticipants (Supplementary Table 5).
Only one participant out of 79 (1%) suffering from moderate eczema was using a TCI (tacrolimus
monohydrate 0.03%, ProtopicÒ, Astellas Pharma Tech Co., Ltd.).
Table 1. Participant characteristics
Demographics n
Mean age, months (SD) 17.0 (12.6) 90
Females, n (%) 39 (43) 90
White, n (%) 57 (73) 78
Mean IMD score (SD) 27.6 (15.3) 88
Eczema severity
Mean EASI (SD) 3.1 (3.4) 79
Mean POEM (SD) 10.3 (5.8) 89
SD = standard deviation. EASI = eczema area severity index. POEM = patient orientated eczema measure.
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Eczema severity and topical corticosteroid potency
Figure 2 compares TCSs potency use with clinical, EASI, and POEM assessments of eczema severity
(Figure 2). Regarding the clinical eczema severity assessment, 86% (18/21) and 19% (3/16) of partici-
pants who reported using a potency of TCSs that ‘matched’ their ‘mild’ and ‘moderate’ eczema
severity, respectively. None of the three participants with ‘severe’ eczema reported using a potent
or very potent TCS.
With respect to eczema severity according to EASI, 91% (21/23) of ‘mild’ and 14% (1/7) of ‘mod-
erate’ eczema sufferers reported using a mild and moderate potency TCSs, respectively. The one
participant assessed as ‘severe’ eczema was not treated with a potent or very potent TCSs.
Regarding eczema severity based on POEM, 75% (3/4) participants with ‘mild’ eczema reported
using a mild potency TCS. However, one participant considered as ‘clear’ or ‘almost clear’ reported
use of a potent TCSs.
It was hypothesised that reported use of TCSs by potency might be related to the age of the par-
ticipants, especially for moderate and potent TCSs. As Figure 3 shows, age of the participantres-
ponder, and the potency of the TCSs used did not appear to be associated.
Discussion
Summary
This is the first study to compare the diagnosis, assessment, and treatment of children with eczema
in primary care with published diagnostic criteria and treatment guidance. Less than half (46%) of
the participants recruited met the UK diagnostic criteria for atopic dermatitis. Agreement between
clinical and categorised parent-reported (POEM) and observer ’objective’ (EASI) assessments of
severity was low (44% and 48%, respectively). A significant proportion of responders (44%) were not
using any emollient, and there was poor concordance between eczema severity (according to clini-
cal, EASI, and POEM) and reported potency of TCSs used. Children with ‘moderate’, ‘severe’ or
‘very severe’ eczema (categorised by any assessment measure) were most likely to report using a
mild TCS.
Strengths and limitations
Linked data on eczema diagnosis, severity (using three different methods) and treatment are pre-
sented for the first time. However, these data were collected as part of a feasibility study and thus
comprise a modest number of participants who may not be representative of all children with
eczema. Indeed, participants recruited into the study via the ‘in consultation’ pathway were younger
and had higher baseline POEM scores, compared with those children recruited via the ‘self-referral’
pathway in the COMET study.9 Missing data, by virtue of incomplete questionnaires or failure to
attend the baseline appointment, further reduced the number of respondersparticipants who could
be inluded in some of the analyses. Clinical assessments were done by 26 different HCPs and no
data on inter-rater reliability was available. While it is possible that HCPs assessments could have
been influenced by parents/carers completing the POEM questionnaire in front of them, this seems
Table 2. Eczema severity by method of assessment
Number of children (%)
Severity Clinical POEM EASI
Clear 4 (4) 7 (8) 22 (28)
Mild 55 (61) 12 (24) 48 (61)
Moderate 28 (31) 50 (56) 8 (10)
Severe 33 (3) 11 (12) 1 (1)
Total 90 (100) 89 (100) 79 (100)
POEM = patient orientated eczema measure. EASI = eczema area severity index.
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Figure 2. Topical corticosteroid use by categorical clinical, EASI, and POEM assessments of eczema severity.
TCS = topical corticosteroid.
Figure 2 continued on next page
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unlikely, given the low level of agreement with EASI. One surgery recruited children to the study via
the ‘in-consultation’ pathway particularly well, and as a consequence, the nurse and GP from this
practice contributed 36% of the assessments, which included 50% of all nurse and 27% of all doctor
assessments. Parent-reported use of medication may be unreliable and this was not compared
against prescription data. Fluctuations in eczema severity in the time between the collection of the
clinical and POEM assessments in the GP practice consultation and EASI at the baseline visit may
explain some of the differences between these measures. Furthermore, the clinical and EASI assess-
ments are based on clinical review of the evidence of eczema, whereas POEM asks the parent/carer
about eczema symptoms (including itch and sleep disturbance) over the previous week.
Comparison with existing literature
Eczema is a clinical diagnosis13 and the UK diagnostic criteria remain the most extensively validated
instrument for defining atopic eczema and dermatitis.14 They perform well in children
aged 3 years, but the diagnosis can be more difficult in infants.15 This may explain some of the dis-
crepancy between the number of children with a clinical diagnosis of eczema and those meeting the
UK diagnostic criteria for eczema.
There is no ’gold standard’ for assessing eczema severity. POEM and EASI are validated patient-
reported and ’objective’ measures of eczema severity, recommended as core outcome measures in
trials of eczema treatments.16 The discordance between clinical assessment and these two measures
Figure 2 continued
EASI = Eczema Area Severity Index.
POEM = Patient Orientated Eczema Measure.
Figure 3. Topical corticosteroid potency by participant age.
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may be due to one of three reasons. First, the published categorisations of eczema severity for
POEM and EASI could be wrong.17–18 This seems unlikely, as they have been derived using appro-
priate methods. Second, the different assessments are evaluating different aspects of childhood
eczema. The clinical assessment is a global impression of severity, subject to individual clinician
biases, and POEM is a measure of symptoms in the affected child over the previous week,10 whereas
EASI relies purely on clinical signs at one point in time.12 Third, the categories of clinical assessment
may be too crude. The NICE categories and descriptions were based on guideline group consensus,
and are not underpinned by any research into their validity or utility.7
Published data regarding the use of treatments for eczema, with which to compare these find-
ings, are limited. Santer and colleagues8 reported that emollients are underprescribed and that
15.9% of children were prescribed a potent or very potent TCSs. Adherence to topical treatments
adherence declines over time,19–20 which may explain some of these findings. Much has been writ-
ten about ‘TCSs phobia’,21 which may explain the low appropriate use of moderate or more potent
TCSs among parents or carers, but this data could possibly also reflects underprescribing by primary
care HCPs.22 Another reason for the apparent underuse of TCSs may be due to sensitivity of the
treatment area, such as the face.23 Finally while the use of TCSs of a greater potency than disease
severity by one category (for example, mild potency TCSs in children with clear or almost clear
eczema), may be appropriate and reflect treatment ‘success’ (maintenance of disease remission), it is
difficult to see how the reported use of potent or very potent TCSs in children with ‘clear’ or ‘almost
clear’ eczema is justified.
Implications for research and clinical practice
Studies of this type need replicating in larger populations with a wider range of clinicians and with
further analyses of inter-rater reliability. Further work is also required to validate the NICE global
assessment of eczema severity, ideally in relation to measures such as the POEM and EASI. Finally,
research should be undertaken to explore the discrepancy between diagnostic criteria and treatment
guidelines. This should not only seek to understand the reasons why, but also the consequences of,
under- or over- treatment of eczema and short- and longer-term outcomes, including adverse
effects.
In the meantime, primary care clinicians should heed concerns about diagnosis of eczema in
infants, in particular distinguishing between eczema and seborrheic dermatitis.24–25 They should also
confirm that patients with eczema prescribed a TCS are using an emollient alongside, and ensure
that the potency of TCSs being used is appropriate for the eczema severity and site. They may want
to consider routinely asking parents of children with eczema to complete the POEM.26 Unlike the
NICE clinical global assessment categories of severity, POEM has been validated and provides infor-
mation on the effect of the disease on the child, which cannot be determined from physical examina-
tion alone.
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Appendix 1
Box S1. UK Atopic dermatitis diagnosis criteria
In order to qualify as a case of atopic eczema with the UK diagnostic criteria, the child:
Must have:
. History of itchy skin
Plus three or more of:
. Onset under the age of 2 (not used in children under 4 years)
. History of flexural involvement (antecubital or popliteal fossa, front of ankles, wrists, or
neck)
. History of a generally dry skin in the last 12 months
. Personal history of other atopic disease (in children aged under 4 years, history of atopic
disease in a first degree relative may be included)
. Visible flexural dermatitis as per photographic protocol
Table S1. Clinical assessment of eczema severity by healthcare professional
No (%)
Severity GP Nurse PP Total
Clear 2 (4) 2 (6) 0 (0) 4 (4)
Mild 34 (61) 19 (59) 2 (100) 55 (61)
Moderate 17 (30) 11 (34) 0 (0) 28 (31)
Severe 3 (5) 0 (0) 0 (0) 3 (3)
Total 56 (100) 32 (100) 2 (100) 90 (100)
Table S2. Clinical and EASI assessments of eczema severity
EASI
Clinical Clear or nearly clear Mild Moderate Severe or very severe Total
Clear 1 1 0 0 2
Mild 17 30 3 0 50
Moderate 4 15 4 1 24
Severe 0 2 1 0 3
Total 22 48 8 1 79
Table S3. Clinical and POEM assessments of eczema severity.
POEM
Clinical Clear or nearly clear Mild Moderate Severe or very severe Total
Clear 3 0 1 0 4
Mild 3 20 30 2 55
Moderate 1 1 18 7 27
Severe 0 0 1 2 3
Total 7 21 50 11 89
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Table S4. Most commonly (reported by five or more participants) used emollients
Name of emollient Number of children prescribed (n = 79)
AveenoÒ 9
OilatumÒ 8
CetrabenÒ 6
DiprobaseÒ 6
DoublebaseÒ 5
E45Ò 5
EpadermÒ 5
HydromolÒ 5
Table S5. Most commonly (reported by two or more participants) used
topical corticosteroids
Name of topical corticosteroid Potency
Number of children prescribed
(n = 79)
Hydrocortisone 1% (Dioderm, Mildison) Mild 21
Hydrocortisone 0.5% Mild 10
Hydrocortisone acetate 1% + fusidic acid 2%
(Fucidin HÒ)
Mild 3
Betamethasone valerate 0.1% (BetnovateÒ) Potent 2
Clobetasone butyrate 0.05% (EumovateÒ) Moderate 2
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